Lower neutrophil‐to‐lymphocyte ratio and positive programmed cell death ligand‐1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma-Reference-Cited by-同舟云学术

Lower neutrophil‐to‐lymphocyte ratio and positive programmed cell death ligand‐1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma

Published:2022-06-14 Issue:22 Volume:11 Page:4236-4245
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Miyama Yu¹^ORCID,Kaneko Go²,Nishimoto Koshiro²,Yasuda Masanori¹

Affiliation:

1. Department of Pathology Saitama Medical University International Medical Center Saitama Japan

2. Department of Uro‐Oncology Saitama Medical University International Medical Center Saitama Japan

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4779

Reference34 articles.

1. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

2. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

3. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

4. Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

5. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity;Frontiers in Cardiovascular Medicine;2024-06-10

2. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma;Frontiers in Immunology;2024-05-10

3. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18

4. Enfortumab vedotin prolonged overall survival in metastatic urothelial carcinoma compared to standard of care following pembrolizumab treatment;2023-10-06

5. Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab;International Journal of Clinical Oncology;2023-04-27